Effectiveness of Various Dosages and Administration Methods of Tanezumab for the Treatment of Pain in Knee and Hip Osteoarthritis: a Network Meta-Analysis

• Published in: Clinical therapeutics 2021-12, Vol.43 (12), p.2116-2126
• Main Authors: Cai, You-zhi, Nie, Liu-yan, Ruan, Jia-qi, Zhao, Kun
• Format: Article
• Language: English
• Subjects: Analgesics; Antibodies, Monoclonal, Humanized; Arthritis; Bias; Biomedical materials; Clinical trials; Double-Blind Method; Drug dosages; effectiveness; Heterogeneity; hip or knee osteoarthritis; Humans; Injection; Intervention; Intravenous administration; Meta-analysis; Network Meta-Analysis; Osteoarthritis; Osteoarthritis, Hip - complications; Osteoarthritis, Hip - drug therapy; Osteoarthritis, Knee - complications; Osteoarthritis, Knee - drug therapy; Pain; Pain Measurement; Patients; Programming languages; Ranking; tanezumab; Treatment Outcome
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2021.10.011

Previous meta-analyses have reported the superiority of tanezumab versus placebo in the treatment of osteoarthritis (OA). However, they did not compare different injection methods (intravenous or subcutaneous), doses of injection. The goal of this network meta-analysis (NMA) was to evaluate the therapeutic effects of different dosages and methods of injection of tanezumab on relieving pain in patients with OA. An online systematic search was performed by using the PubMed, Cochrane Library, EMBASE, and ClinicalTrials.gov databases from inception to November 9, 2019. The goal was to identify randomized controlled trials (RCTs) that concentrated on the therapeutic effects of different dosages and methods of injection of tanezumab in patients with OA. The pairwise meta-analyses with the fixed effects model were undertaken with the “meta” package using R 3.6.0 programming language. In addition, an NMA with fixed effects was assessed using a gemtc software. The surface under the cumulative ranking curve value of each intervention was calculated to obtain a hierarchy of treatments. Of the 328 RCTs identified through the literature search, 12 RCTs were included in the current NMA. In terms of the Western Ontario and McMaster Universities Osteoarthritis Index pain and physical function subscales, the most effective treatment was intravenous injection of tanezumab (10 mg; surface under the cumulative ranking curve values of 90% and 88%, respectively), and the least effective therapy was subcutaneous injection of tanezumab (2.5 mg; 20% and 19%). To achieve high therapeutic efficacy and avoid treatment failure, an intravenous injection of tanezumab (10 mg) is recommended as an efficacious therapy, facilitating pain relief in patients with OA. However, this conclusion may also be affected by the limitations of this study owing to the small sample size and data heterogeneity, and further research should therefore be conducted to eliminate these limitations and to confirm the findings.